Quality Management at the European BNCT Center in Petten

  • W. Sauerwein
  • R. L. Moss
  • J. Rassow
  • F. Stecher-Rasmussen
  • K. Hideghéty
  • S. Garbe
  • J. G. Wolbers
  • D. Gabel
  • P. Watkins
  • C. Vroegindeweij
  • H. Sack

Abstract

Boron Neutron Capture Therapy is based on the ability of the isotope 10B to capture thermal neutrons and to disintegrate instantaneously producing the high LET particles, He and Li nuclei, with a high kinetic energy of about 2.5 MeV and a very short range in tissue of about 10μm [10B(n,α)7Li]. If such reactions can be produced selectively in tumour cells, an effective new modality for cancer treatment would be available. In the 1950’s and early 1960’s, BNCT trials in the USA were effectively a failure.1 Nevertheless, in the late 60’s, Hatanaka in Japan demonstrated that BNCT does benefit patients.2 However, the reported results were difficult to interpret, because the treatment was not carried out in a controlled manner. In 1994, new trials started in the USA (at Brookhaven National Laboratory BNL3 and Massachusetts Institute of Technology MIT4) involving glioblastoma (at BNL and MIT) and melanoma (at MIT). Meanwhile in Europe in the late 1980’s, effective research into introducing BNCT began following the injection of financial support from the Biomedicine and Health Research programme (BIOMED I) of the European Commission. This has lead recently to the start of clinical trials of BNCT for glioblastoma multiforme, with the aim to establish a safe radiation dose for the treatment of brain tumours.5 It is the first time that a clinical application has had to be realised on a real multi-national scale, whereby a unique facility available for BNCT is localised in one country (The Netherlands) and is operated by an international team of experts under the leadership of a German radiotherapist, treating patients coming from different European countries. It was therefore necessary that special structures had to be created with the support of administrations from different countries, who had to find and adapt solutions within existing laws that had never foreseen such a situation.

Keywords

Europe Boron Esca Boronophenylalanine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Slatkin, D.N., “A history of boron neutron capture therapy of brain tumours”, Brain, 114, 1991.Google Scholar
  2. 2.
    Hatanaka, H. et al., “Clinical experience of boron-neutron capture therapy for gliomas-a comparison with conventional chemo-immuno-radiotherapy”, in Boron-Neutron Capture Therapy for Tumours, Ed. H. Hatanaka, Niigata, Japan: Nishimura, 1986.Google Scholar
  3. 3.
    Coderre, J.A., “BNCT for malignant glioma using BPA”, Proc. 6th Int. Symp. on Neutron Capture Therapy, Kobe, Japan, November 1994; Ed. Y.Mishima, Plenum Press, New York, 1995.Google Scholar
  4. 4.
    Madoc-Jones, H., Zamenhof, R., Solares, R., and Harling, O., “Clinical trial begins at MIT/NEMC”, idem.Google Scholar
  5. 5.
    Sauerwein, W., Gabel, D., and Fankhauser, H., “Glioma BNCT. Postoperative treatment of glioblas- toma with BNCT at the Petten irradiation facility. 1. Phase I clinical trial”, EORTC Protocol 11691, March 1997.Google Scholar
  6. 6.
    Gabel, D., “Approach to Boron Neutron Capture Therapy in Europe: Goals of a European Collabora- tion on Boron Neutron Capture Therapy”, Proc. 2nd. Eur. Particle Accelerator Conf., Nice, 1990.Google Scholar
  7. 7.
    Ahlf, J., Zurita, A., eds., “High Flux Reactor (HFR) Petten, Characteristics of the Installation and the Irradiation Facilities”, EUR 15151 EN, 1993.Google Scholar
  8. 8.
    Moss, R.L., Casado, J., Ravensberg, K., Stecher-Rasmussen F., and Watkins, P., “The Completed BNCT Facility at the HFR Petten”, 7th Int. Symp. on Neutron Capture Therapy, Zurich, September 1996; Ed. B. Larsson, J. Crawford, Plenum Press, New York, 1997.Google Scholar
  9. 9.
    Raaijmakers, C.P.J., Konijnenberg, M.W., Dewit, L., Haritz, D., Huiskamp, R., Philipp, K., Siefert, A., Stecher-Rasmussen, F., and Mijnheer, B.J., “Monitoring of blood-10 B concentration for boron neutron capture therapy using prompt gamma-ray analysis”, Acta Oncologica 34, 517-523 (1995).PubMedCrossRefGoogle Scholar
  10. 10.
    Gregoire, V., Begg, A.C., Huiskamp, H., Verrijk, R., and Bartelink, H., “Selectivity of boron carriers for boron neutron capture therapy: pharmacological studies with borocaptate sodium, L-boronophenylalanine and boric acid in murine tumors.”, Radiother.Oncol. 27:46-54, 1993.PubMedCrossRefGoogle Scholar
  11. 11.
    Bohaychuk, W., and Ball, G., “Good Clinical Research Practices, An indexed reference to international guidelines and regulations, with practical interpretation”, GCRP Publications, January 1994.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • W. Sauerwein
    • 1
  • R. L. Moss
    • 2
  • J. Rassow
    • 1
  • F. Stecher-Rasmussen
    • 3
  • K. Hideghéty
    • 1
  • S. Garbe
    • 1
  • J. G. Wolbers
    • 4
  • D. Gabel
    • 5
  • P. Watkins
    • 2
  • C. Vroegindeweij
    • 2
  • H. Sack
    • 1
  1. 1.Department of RadiotherapyUniversity of EssenGermany
  2. 2.HFR Unit, Joint Research CentreEuropean CommissionPettenThe Netherlands
  3. 3.Business Unit Nuclear EnergyECNPettenThe Netherlands
  4. 4.Department of NeurosurgeryVUAmsterdamThe Netherlands
  5. 5.Department of ChemistryUniversity of BremenGermany

Personalised recommendations